TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
Open Access
- 29 October 2019
- journal article
- review article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 69 (2) , 237-244
Abstract
The TAM receptors—TYRO3, AXL, MERTK—are pleiotropically expressed receptors in both healthy and diseased tissue. A complex of the ligands Protein S (PROS1) or Growth Arrest-Specific 6 (GAS6) with apoptotic phosphatidylserine activates the TAM receptors. Hence, this receptor family is essential for the efferocytosis of apoptotic material by antigen-presenting cells. In addition, TAM receptors are expressed by virtually all cells of the tumor microenvironment. They are also potent oncogenes, frequently overexpressed in cancer and involved in survival and therapy resistance. Due to their pro-oncogenic and immune-inhibitory traits, TAM receptors have emerged as promising targets for cancer therapy. Recently, TAM receptors have been described to function as costimulatory molecules on human T cells. TAM receptors’ ambivalent functions on many different cell types therefore make therapeutic targeting not straight-forward. In this review we summarize our current knowledge of the function of TAM receptors in the tumor microenvironment. We place particular focus on TAM receptors and the recently unraveled role of MERTK in activated T cells and potential consequences for anti-tumor immunity.Keywords
Funding Information
- H2020 Marie Skłodowska-Curie Actions (641549, 641549)
This publication has 49 references indexed in Scilit:
- Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase InhibitorCancer Research, 2019
- MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunityJCI Insight, 2018
- TAM Receptor Tyrosine Kinases in Cancer Drug ResistanceCancer Research, 2017
- UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia ModelsClinical Cancer Research, 2017
- TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapyImmunological Reviews, 2017
- Diversification of TAM receptor tyrosine kinase functionNature Immunology, 2014
- Increased expression of Mer tyrosine kinase in circulating dendritic cells and monocytes of lupus patients: correlations with plasma interferon activity and steroid therapyArthritis Research & Therapy, 2014
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cellsNature, 2014
- Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activityProceedings of the National Academy of Sciences, 1997
- An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous systemNeuron, 1991